Neil Kumar, PhD
Founder & Chief Executive Officer at BridgeBio Pharma
Director
Neil is the Chief Executive Officer and Founder of BridgeBio Pharma, Inc., a company working to create life-altering medicines that target well-characterized genetic diseases at their source. He has also served as the Chief Executive Officer of BridgeBio’s subsidiary, Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company, and a member of Eidos Therapeutics’ board of directors since March 2016. Before founding BridgeBio in 2015, Neil was a Principal at Third Rock Ventures, supporting and managing portfolio companies, while also focusing on new company formation and due diligence. During his time at Third Rock, he served as the interim Vice President of Business Development and Operations for MyoKardia. Prior to joining Third Rock, Neil was an Associate Principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s personalized medicine efforts. Neil holds BS and MS degrees in Chemical Engineering from Stanford University. He received his PhD in Chemical Engineering from the Massachusetts Institute of Technology (MIT).